Recent Advancements in Lung Cancer Metastasis Prevention Based on Nanostrategies
Advanced Science,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 26, 2025
Metastasis
is
the
leading
cause
of
death
in
patients
with
lung
cancer.
Multidisciplinary
comprehensive
treatments
(MDT),
including
surgery,
chemotherapy,
radiotherapy,
gene-targeted
therapy,
immunotherapy,
antibody-drug
conjugate
(ADC),
natural
products,
etc.,
have
been
currently
used
for
cancer
metastasis.
The
MDT
model
has
shown
promising
efficacy
against
metastasis
clinical
practice.
However,
these
therapies
some
limitations,
such
as
unusual
toxic
side
effects,
drug
resistance,
limited
indications,
and
high
costs.
Therefore,
emerging
technological
platforms
are
imperative
to
overcome
bottlenecks.
Nanomedicine
can
be
prepare
efficient
delivery
systems
owing
its
good
biocompatibility,
targeting,
responsive
release,
multidrug
codelivery
plays
an
important
role
synergistic
antimetastasis
because
optical,
acoustic,
electrical,
thermal,
magnetic
functions.
This
review
analyses
limitations
model,
briefly
outlines
advantages
nanotechnology,
introduces
nanodrug
systems,
summarizes
nanostrategies
based
on
invasion-metastasis
cascade
process,
provides
a
summary
prospects
challenges
translation
nanomedicines.
Язык: Английский
In-situ activated arsenic-molybdenum dual-prodrug nanocomplexes for glutathione-depletion enhanced photothermal/chemotherapy against triple-negative breast cancer
He Li,
WeiYi Cheng,
WeiYe Ren
и другие.
Chemical Engineering Journal,
Год журнала:
2024,
Номер
497, С. 155075 - 155075
Опубликована: Авг. 23, 2024
Язык: Английский
Bioorthogonal Chemistry-Guided Inhalable Nanoprodrug to Circumvent Cisplatin Resistance in Orthotopic Nonsmall Cell Lung Cancer
ACS Nano,
Год журнала:
2024,
Номер
18(46), С. 32103 - 32117
Опубликована: Ноя. 9, 2024
Pulmonary
delivery
of
anticancer
therapeutics
has
shown
encouraging
performance
in
treating
nonsmall
cell
lung
cancer
(NSCLC),
which
is
characterized
by
high
aggressiveness
and
poor
prognosis.
Cisplatin,
a
key
member
the
family
DNA
alkylating
agents,
extensively
employed
during
NSCLC
therapy.
However,
development
chemoresistance
occurrence
side
effects
severely
impede
long-term
application
cisplatin-based
chemotherapies.
Herein,
we
propose
meaningful
strategy
to
precisely
treat
cisplatin-resistant
based
on
combination
bioorthogonal
chemistry
with
an
inhalation
approach.
Ethacraplatin
(EA-Pt),
platinum
prodrug
(IV),
was
synthesized
encapsulated
nitric
oxide
(NO)-containing
micelles
overcome
cisplatin
chemoresistance.
By
further
modifying
molecules
this
nanoplatform
(EA-Pt@M
Язык: Английский